Status:
RECRUITING
Microvascular Angina Intervention With Compound Danshen Dripping Pill (MAIDS)
Lead Sponsor:
Qilu Hospital of Shandong University
Conditions:
Microvascular Angina
Eligibility:
All Genders
30-75 years
Phase:
PHASE4
Brief Summary
Coronary microvascular disease (MVD) refers to exertional angina or myocardial ischemia caused by abnormal structure and/or function of precoronary arterioles and arterioles under the action of variou...
Detailed Description
1. Research Background Coronary microvascular disease (MVD) is a clinical syndrome refers to laboratory evidence of exertional angina or myocardial ischemia caused by structural and/or functional abno...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- with typical symptoms of exertional angina;
- coronary CTA or angiography with normal coronary artery or \<50% stenosis, or \<50% residual coronary stenosis after revascularization;
- resting electrocardiogram or During exercise stress, it was found that the ST segment had an ischemic downward shift (the horizontal or downward slope after the J-point shift \> 0.1 mv, lasting 0.08 s);
- Transthoracic ultrasound examination of blood in the anterior descending coronary artery before and after intravenous injection of adenosine Flow reserve check CFR\<2.5;
- The patient himself agrees to participate in this study.
- Exclusion criteria
- Less than 30 years old or more than 75 years old;
- Have a history of carotid endarterectomy or stent implantation, and have a history of stroke;
- Myocarditis, pericardial disease, valvular disease, cardiomyopathy;
- Difficult to control diabetes mellitus (fasting blood glucose\>7.0 mmol/L);
- Uncontrolled hypertension (SBP\>150 mmHg and/or DBP\>90 mmHg);
- Familial hypercholesterolemia;
- Multiple Takayasu arteritis;
- Those who are pregnant or lactating, or have fertility intention within one year, or have not taken effective contraceptive measures during the childbearing period;
- Abnormal liver function (the level of serum GPT is 3.0 times higher than the upper limit of normal value) or abnormal renal function (the level of serum creatinine is more than 2 mg/dl);
- Other respiratory, digestive, blood, infection, immunity, endocrine, neuropsychiatric, tumor diseases with clinical significance that may cause serious danger to patients;
- Taking traditional Chinese medicine preparations of K channel opener, promoting blood circulation and removing blood stasis to improve microcirculation;
- Allergies to intra arterial injection of contrast agents, blood and blood products;
- Patients who are participating in other clinical studies.
Exclusion
Key Trial Info
Start Date :
December 18 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2028
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06092736
Start Date
December 18 2018
End Date
June 30 2028
Last Update
October 23 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Qilu Hospital of Shandong University
Jinan, Shandong, China, 250012